Grifols, S.A. (BME: GRF)
Spain
· Delayed Price · Currency is EUR | Market Cap | 6.60B |
| Revenue (ttm) | 7.01B |
| Net Income (ttm) | 161.49M |
| Shares Out | 679.63M |
| EPS (ttm) | 0.24 |
| PE Ratio | 44.61 |
| Forward PE | 12.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,246,068 |
| Open | 10.44 |
| Previous Close | 10.40 |
| Day's Range | 10.41 - 10.68 |
| 52-Week Range | 6.36 - 15.92 |
| Beta | 0.72 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2024 |
About Grifols
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and... [Read more]
Financial Performance
In 2023, Grifols's revenue was 6.59 billion, an increase of 8.71% compared to the previous year's 6.06 billion. Earnings were 59.32 million, a decrease of -71.52%.
Financial StatementsNews
Key deals this week: Amcor, ONEOK, Grifols, N-able and more
Brookfield considers US$6.9 billion bid for Grifols; shares dip
Grifols Class A shares declined as much as 6.7% after the statements were published
Grifols slips as Brookfield said to mull $6.9B offer
Grifols: Brookfields potential $6.8 bln offer undervalues the firm
Grifols said on Tuesday that Canadian investment fund Brookfield's potential 6.45 billion euro ($6.8 billion) offer significantly undervalued the Spanish drugmaker's prospects and long-term potential.
Brookfield Weighs €6.45 Billion Bid for Grifols; Shares Drop
Brookfield Asset Management is considering a €6.45 billion ($6.9 billion) bid for Grifols SA, with the drug maker’s board set to meet Tuesday to discuss the potential offer. Grifols’s shares fell.
Spanish court opens investigation into Gotham City's attack on Grifols
An investigating magistrate at the Spanish High Court said on Tuesday it had opened an investigation into U.S.-based short seller Gotham City's actions that brought down the share price of Spanish pha...
Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...
Brookfield mulls $7.4 bln bid for Spain's Grifols, El Confidencial says
Canadian fund Brookfield plans to offer about 7 billion euros ($7.4 billion) for Spanish drugmaker Grifols after finishing due diligence, news website El Confidencial reported on Monday, citing source...
Brandes Builds Grifols Stake as Investors Await Brookfield Bid
Brandes Investment Partners LP has built a stake in Grifols SA as investors wait for Brookfield Asset Management to make an offer for the Spanish drugmaker.
Brandes Investment Partners, LP Reduces Stake in Grifols SA
Brandes Investment Partners, LP Reduces Stake in Grifols SA
Grifols spikes as banks reportedly finalize offers for buyout debt deal
Banks to Pitch Roughly €11 Billion Buyout Debt for Grifols
Banks are getting ready to submit final offers to Brookfield Asset Management for a debt package of about €11 billion ($11.6 billion) to back the take-private of Spanish pharmaceutical producer Grifol...
Grifols SA (GIFLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Cash ...
Grifols SA (GIFLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Cash Flow Amid Challenges
Q3 2024 Grifols SA Earnings Call Transcript
Q3 2024 Grifols SA Earnings Call Transcript
Grifols holder Mason Capital against potential Brookfield deal
Mason Capital opposes Grifols sale to Brookfield Asset Management, raising concerns about the potential acquisition in the pharmaceutical industry.
Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors
NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols S.A. (“Grifols” or the “Company”) (BME: G...
Grifols on track to meet 2024 targets despite third-quarter profit drop
Spanish drugmaker Grifols said on Thursday it was on track to meet its targets for the year after its net profit fell 7.5% in the third quarter from the same period a year ago.
Grifols gains after report Brookfield still pursuing possible takeover
Grifols stock rose as Brookfield Asset Management continues to evaluate a takeover, pending information on related-party transactions.
Brookfield Seeks More Information on Grifols Related-Party Deals
Brookfield Asset Management is awaiting information from Grifols SA about related-party transactions as it seeks to complete its due diligence on the business, according to a person familiar with the ...
Grifols falls on report Brookfield delays offer on funding issues
Grifols stock falls as Brookfield delays takeover bid due to financial challenges, including raising €9.5 billion for debt repayment.
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down
Brookfield asks for more time to weigh potential Grifols deal - report
Brookfield Asset Management asks for more time to consider bid for Grifols as it considers taking the Spanish healthcare company private. Read more here.
Brookfield to Request More Time for Grifols Due Diligence
Brookfield Asset Management is set to request more time to conduct due diligence on Spanish drugmaker Grifols SA, according to a person familiar with the matter.
Grifols plans to invest $402 million in new industrial centre, El Economista says
Spanish drugmaker Grifols plans to invest 360 million euros ($401.98 million) to build a new industrial plant in Barcelona for its engineering department, newspaper El Economista said on Monday, citin...
Grifols Accelerates Plan to Cut Chairman’s Executive Powers
Grifols SA has accelerated a plan to cut Chairman Thomas Glanzmann’s executive powers, as the Spanish drug-maker seeks to bolster its corporate governance amid a takeover approach.